El Palivizumab constituye el primer hito destacable en la prevención del VRS en grupos de alto riesgo, marcando un punto de inflexión en nuestra capacidad de lucha contra este virus. Reflexionamos con uno de los mayores expertos sobre este tema, el Dr. Sánchez Luna, revisamos la experiencia acumulada en estos años, las lecciones aprendidas, los retos pendientes, y alguna cosa más.

Por algún sitio tenía que empezar esta nueva experiencia podcast, y pensamos que hablando con dos expertos de la talla de Mara Garces y Manuel Sánchez Luna, podríamos hacer una visión 360 sobre el VRS, a partir de un documento, el decálogo VRS, que se ha presentado recientemente en sociedad y que revisa de forma práctica el estado de la cuestión y las acciones necesarias para abordar este problema de salud global.

Una de las cosas que más nos preocupa cuando hablamos de infección por VRS son las potenciales secuelas pulmonares que puede padecer el paciente que ha sufrido dicha infección (hiperreactividad bronquial, Asma, etc…) El Dr. Antonio Moreno, experto en patología respiratoria pediátrica nos aclara algunas dudas al respecto.

Dive into the captivating world of Respiratory Syncytial Virus (RSV) research with the latest episode of the RSV Academy podcast. Hosted by the esteemed Professor Federico Martinón-Torres from the University of Santiago, this episode promises a deep dive into the intricacies of RSV and its broader implications in the realm of virology. Our special guest for this episode of the RSV Academy podcast is none other than Dr. Barney Graham, a pioneer in the field of RSV research. As the Deputy Director of the Vaccine Research Center and the Chief of the Viral Pathogenesis Laboratory at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Dr. Graham's contributions have revolutionized our understanding of RSV. His groundbreaking work in structural vaccinology has not only advanced RSV research but has also been instrumental in the rapid development of vaccines for other pathogens, including very importantly COVID-19, but also Zika or influenza. In this enlightening discussion, listeners will gain insights into the significance of the pre-F structure in RSV vaccine development, the wonderful and difficult path needed to achieve it and how from a basic approach trying to solve a safety issue the RSV field was revolution, or the challenges in dealing with different age groups or aiming the eradication of RSV given its exclusive human reservoir. Furthermore, the episode delves into the lessons from RSV research that can be applied to other respiratory viruses and the strategic priorities for RSV vaccine development. Aspiring researchers and students will also benefit from Dr. Graham's invaluable advice on making a mark in the field of virology and immunology. Don't miss out on this opportunity to learn from one of the leading figures in RSV research. Tune in to the RSV Academy podcast for a comprehensive understanding of the current landscape and future trajectory of RSV research.

Welcome to a new episode of the RSV ACADEMY podcast, where explore the ever-evolving world of Respiratory Syncytial Virus (RSV). In this episode, we are honored to have Professor Harish Nair, a leading epidemiologist based at the University of Edinburgh, as our guest. With a career dedicated to understanding the epidemiology, burden, and prevention of RSV, Professor Nair's work has been instrumental in shaping global health policies. He has led several large collaborative projects like PROMISE, RESCEU, and RSV GEN and is a co-founder of ReSVinet. In this enlightening conversation, we tackle some of the most pressing questions in RSV research. How many deaths does RSV actually cause each year? What is the true burden of RSV in older adults? Professor Nair shares groundbreaking insights from his recent studies, shedding light on the underestimated impact of RSV, particularly in older adults. We also explore the epidemiological gaps in our understanding of RSV, including its seasonality and the effects of co-infections. One of the episode's highlights is the discussion on current country recommendations and positioning on RSV prophylaxis. Should it be seasonal or administered all year round? Is it all about cost-effectiveness? Professor Nair provides a nuanced perspective on these complex issues, emphasizing the need for a strategic approach based on regional epidemiology and healthcare system capacity. As RSV vaccines become a reality, how can they be effectively integrated into the Expanded Program on Immunization (EPI)? Professor Nair outlines the challenges and opportunities, from supply chain logistics to healthcare worker training and community engagement. Finally, for young researchers entering this dynamic field, Professor Nair offers invaluable advice on focusing on areas with significant knowledge gaps to make impactful contributions. Don't miss this episode filled with critical insights that promise to deepen your understanding of RSV, its global impact, and the future of its prevention and treatment. Stay tuned for more captivating discussions on RSV ACADEMY, your ultimate guide to the world of RSV.

Prof. Alberto Papi, University of Ferrara, Italy Dive into the captivating realm of Respiratory Syncytial Virus (RSV) with the latest episode of the RSV Academy podcast. Hosted by Prof. Federico Martinon-Torres, this episode offers listeners an exclusive opportunity to gain insights from one of the leading figures in RSV research, Professor Alberto Papi from the University of Ferrara. Professor Papi's groundbreaking work, including his recent publication on the prefusion F Protein Candidate Vaccine (RSVPreF3 OA), has been instrumental in shaping our understanding of RSV, especially in the context of adult prevention. In this episode, listeners will be treated to a deep dive into the significance of RSV in adults, comparing its impact to other respiratory diseases like the flu and understanding its clinical implications. The discussion also touches upon the intricate interactions of RSV with respiratory tract epithelial cells and the potential implications of these interactions for RSV infections. Furthermore, Professor Papi shares his perspective on the recent pratical recommendations of regulatory agencies on RSV vaccines and offers invaluable advice to budding researchers in the field. Whether you're a seasoned professional or someone new to the world of RSV, this episode promises a wealth of knowledge and insights.